Corpus ID: 24419100

In vitro and in vivo biotransformation of 6,7-dimethyl-2,4-di-1-pyrrolidinyl-7H-pyrrolo[2,3-D]pyrimidine (U-89843) in the rat.

@article{Zhao1996InVA,
  title={In vitro and in vivo biotransformation of 6,7-dimethyl-2,4-di-1-pyrrolidinyl-7H-pyrrolo[2,3-D]pyrimidine (U-89843) in the rat.},
  author={Z Y Zhao and Kenneth Koeplinger and Gordon Bundy and Lee S. Banitt and G. E. Padbury and M J Hauer and Phillip E. Sanders},
  journal={Drug metabolism and disposition: the biological fate of chemicals},
  year={1996},
  volume={24 2},
  pages={
          187-98
        }
}
The biotransformation of 6,7-dimethyl-2,4-di-1-pyrrolidinyl-7H-pyrrolo[2,3-d]pyrimidine (U-89843) has been studied in rat both in vitro and in vivo. Major metabolites observed by HPLC analysis of rat plasma, liver cytosol, and microsomal incubations were characterized by UV, LC/MS, and comparison with synthetic standards. The structures of the metabolites were shown to be the C-6 hydroxymethyl (U-97924), C-6 formyl (U-97865), and C-6 carboxyl analogs of U-89843. In the male rat, formation of U… Expand
Contribution of serum protein association to discrepancy between the in vivo and in vitro UDS results for 6,7-dimethyl-2,4-di-1-pyrrolidinyl-7H-pyrrolo[2,3-d]pyrimidine (U-89843).
TLDR
The results suggest that the effect of serum protein should be considered when comparing serum-free in vitro UDS and in vivo UDS results for highly serum protein bound compounds. Expand
Activated sulfonamides are cleaved by glutathione-S-transferases.
In preclinical pharmacokinetic studies and in in vitro rat, dog, and human primary hepatocyte incubations, the sulfonamide (-NH-SO(2)-) bond of a potent inhibitor of the HIV-1 protease containing theExpand
Improving the decision-making process in structural modification of drug candidates: reducing toxicity.
TLDR
This review highlights the strategies for the decision-making process involving substructures that, when found in drugs, can form reactive metabolites and are involved in toxicities in humans; the tools used to reduce IDRs are also discussed. Expand
Minimizing the Potential for Drug Bioactivation of Drug Candidates to Success in Clinical Development
TLDR
The recent efforts to overcome and assess the problem of reactive metabolites in drug discovery and development are discussed, which might help to evaluate the safety profile of new drug candidates for idiosyncratic drug reactions (IDRs) during the preclinical phase. Expand